NZ597975A - Methods and compositions for use in cellular therapies - Google Patents
Methods and compositions for use in cellular therapiesInfo
- Publication number
- NZ597975A NZ597975A NZ597975A NZ59797510A NZ597975A NZ 597975 A NZ597975 A NZ 597975A NZ 597975 A NZ597975 A NZ 597975A NZ 59797510 A NZ59797510 A NZ 59797510A NZ 597975 A NZ597975 A NZ 597975A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- methods
- cellular therapies
- medicament
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22427509P | 2009-07-09 | 2009-07-09 | |
| PCT/IB2010/001968 WO2011004264A1 (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597975A true NZ597975A (en) | 2014-06-27 |
Family
ID=42782196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597975A NZ597975A (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8679834B2 (enExample) |
| EP (2) | EP3150703A1 (enExample) |
| JP (1) | JP5892931B2 (enExample) |
| KR (1) | KR101788885B1 (enExample) |
| CN (2) | CN107007626A (enExample) |
| AU (1) | AU2010269962B2 (enExample) |
| BR (1) | BR112012000534A2 (enExample) |
| CA (1) | CA2767300C (enExample) |
| DK (1) | DK2451943T3 (enExample) |
| ES (1) | ES2479542T3 (enExample) |
| HU (1) | HUE031921T2 (enExample) |
| IL (1) | IL217377A (enExample) |
| MX (1) | MX359639B (enExample) |
| NZ (1) | NZ597975A (enExample) |
| PL (1) | PL2451943T3 (enExample) |
| PT (1) | PT2451943T (enExample) |
| RU (1) | RU2610427C2 (enExample) |
| SG (2) | SG10201403758SA (enExample) |
| WO (1) | WO2011004264A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| CA2623353C (en) | 2005-09-23 | 2017-02-21 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
| US11090363B2 (en) | 2009-07-10 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Vasoactive intestinal peptide release from microparticles |
| WO2011006029A1 (en) | 2009-07-10 | 2011-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Artificial cell constructs for inducing immunological tolerance |
| WO2012095743A2 (en) * | 2011-01-12 | 2012-07-19 | Cellerix Sa | Methods and compositions for use in intralymphatic cellular therapies |
| RS57886B1 (sr) | 2011-11-30 | 2019-01-31 | Astellas Inst For Regenerative Medicine | Mezenhimalne stromalne ćelije i primene vezane za njih |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| CN104822384A (zh) * | 2012-03-30 | 2015-08-05 | 南加州大学 | 用于间充质干细胞诱导的免疫调节的组合物和治疗方法 |
| CA2876499C (en) | 2012-07-12 | 2021-10-26 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| US10258652B2 (en) | 2014-12-18 | 2019-04-16 | Pluristem Ltd. | Methods and compositions for treating and preventing muscle wasting disorders |
| WO2016107563A1 (zh) * | 2014-12-29 | 2016-07-07 | 西比曼生物科技（上海）有限公司 | 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物 |
| US20180015125A1 (en) | 2015-03-23 | 2018-01-18 | Pluristem Ltd. | Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof |
| US20210205370A1 (en) | 2016-02-18 | 2021-07-08 | Pluristem Ltd. | Methods and compositions for treating cancers and neoplasms |
| GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| WO2018002930A1 (en) | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| CA3062123A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
| WO2018211486A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells |
| CN107349419A (zh) * | 2017-07-17 | 2017-11-17 | 广东颜值科技有限公司 | 一种细胞组合物及其制备方法和应用 |
| CN107281469A (zh) * | 2017-07-17 | 2017-10-24 | 广东颜值科技有限公司 | 一种细胞组合物及其制备方法和应用 |
| US12268714B2 (en) | 2018-09-14 | 2025-04-08 | Luca Science Inc. | Transplantation of mitochondria into lymphoid organ and composition therefor |
| US11975030B2 (en) * | 2019-03-19 | 2024-05-07 | Figene, Llc | Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof |
| US11878037B2 (en) | 2019-05-31 | 2024-01-23 | Figene, Llc | Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis |
| WO2021207192A1 (en) * | 2020-04-08 | 2021-10-14 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2493081C (en) * | 2002-07-12 | 2013-04-23 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| EP2260861A1 (en) * | 2002-12-06 | 2010-12-15 | NorthWest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| CA2623353C (en) | 2005-09-23 | 2017-02-21 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| EP2581441A1 (en) * | 2007-08-09 | 2013-04-17 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| US20110262402A1 (en) * | 2007-09-07 | 2011-10-27 | Masahiko Kuroda | Therapeutic and prophylactic agents for arthritis |
| US20110150845A1 (en) * | 2008-05-02 | 2011-06-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating immunological tolerance |
| GB0814249D0 (en) | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
-
2010
- 2010-07-09 WO PCT/IB2010/001968 patent/WO2011004264A1/en not_active Ceased
- 2010-07-09 SG SG10201403758SA patent/SG10201403758SA/en unknown
- 2010-07-09 US US13/382,426 patent/US8679834B2/en active Active
- 2010-07-09 EP EP16199980.0A patent/EP3150703A1/en not_active Withdrawn
- 2010-07-09 CA CA2767300A patent/CA2767300C/en active Active
- 2010-07-09 SG SG2012001574A patent/SG177582A1/en unknown
- 2010-07-09 MX MX2012000396A patent/MX359639B/es active IP Right Grant
- 2010-07-09 AU AU2010269962A patent/AU2010269962B2/en active Active
- 2010-07-09 BR BR112012000534A patent/BR112012000534A2/pt not_active Application Discontinuation
- 2010-07-09 ES ES10752171.8T patent/ES2479542T3/es active Active
- 2010-07-09 CN CN201710067652.0A patent/CN107007626A/zh active Pending
- 2010-07-09 NZ NZ597975A patent/NZ597975A/en unknown
- 2010-07-09 RU RU2012104529A patent/RU2610427C2/ru active
- 2010-07-09 DK DK10752171.8T patent/DK2451943T3/en active
- 2010-07-09 JP JP2012519080A patent/JP5892931B2/ja active Active
- 2010-07-09 HU HUE10752171A patent/HUE031921T2/en unknown
- 2010-07-09 PL PL10752171T patent/PL2451943T3/pl unknown
- 2010-07-09 CN CN2010800308900A patent/CN102549147A/zh active Pending
- 2010-07-09 KR KR1020127003364A patent/KR101788885B1/ko active Active
- 2010-07-09 EP EP10752171.8A patent/EP2451943B1/en active Active
- 2010-07-09 PT PT107521718T patent/PT2451943T/pt unknown
-
2012
- 2012-01-05 IL IL217377A patent/IL217377A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL217377A (en) | 2017-10-31 |
| RU2610427C2 (ru) | 2017-02-10 |
| MX359639B (es) | 2018-10-04 |
| BR112012000534A2 (pt) | 2017-06-13 |
| ES2479542T1 (es) | 2014-08-20 |
| ES2479542T3 (es) | 2017-05-26 |
| CA2767300C (en) | 2020-01-07 |
| US20120308585A1 (en) | 2012-12-06 |
| PT2451943T (pt) | 2017-01-20 |
| DK2451943T3 (en) | 2017-02-06 |
| SG10201403758SA (en) | 2014-10-30 |
| KR101788885B1 (ko) | 2017-10-20 |
| CN107007626A (zh) | 2017-08-04 |
| KR20120051006A (ko) | 2012-05-21 |
| EP3150703A1 (en) | 2017-04-05 |
| CN102549147A (zh) | 2012-07-04 |
| PL2451943T3 (pl) | 2017-04-28 |
| MX2012000396A (es) | 2012-07-17 |
| SG177582A1 (en) | 2012-03-29 |
| JP5892931B2 (ja) | 2016-03-23 |
| IL217377A0 (en) | 2012-02-29 |
| HUE031921T2 (en) | 2017-08-28 |
| RU2012104529A (ru) | 2013-08-20 |
| AU2010269962B2 (en) | 2016-04-14 |
| EP2451943A1 (en) | 2012-05-16 |
| WO2011004264A1 (en) | 2011-01-13 |
| AU2010269962A1 (en) | 2012-03-01 |
| JP2012532859A (ja) | 2012-12-20 |
| CA2767300A1 (en) | 2011-01-13 |
| US8679834B2 (en) | 2014-03-25 |
| EP2451943B1 (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY164356A (en) | Substituted 5-fluoro-1h-pyrazolopyridines and their use | |
| MY185016A (en) | Progenitor cells of mesodermal lineage | |
| GB2482536B (en) | Expression of antibody or a fragment thereof in lactobacillus | |
| IN2012DN01920A (enExample) | ||
| MY165086A (en) | Formulations of rifaximin and uses thereof | |
| MX2009009079A (es) | Anticuerpos anti-il-23p19 de ingenieria. | |
| MX2009009080A (es) | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. | |
| IN2014DN06104A (enExample) | ||
| MX2011009033A (es) | Inhibidores triciclicos de cinasa pirazolopiridina. | |
| MX2012000949A (es) | Terapias de combinacion con moduladores de ck2. | |
| MX365650B (es) | Composiciones de amantadina y metodos para su uso. | |
| IL207310A0 (en) | Vaccine compositions | |
| MY170934A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| WO2014210037A3 (en) | A composition of mesenchymal stem cells | |
| WO2012095743A3 (en) | Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases | |
| TN2015000048A1 (en) | Methods of administering rifaximin for weight loss and treatment of obesity | |
| MX342239B (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| MX2011009277A (es) | Composicion de leucocito activada. | |
| WO2012006585A3 (en) | Use of interleukin-15 to treat cardiovascular diseases | |
| PH12014500739B1 (en) | Methods for treating a stroke-related sensorimotor impairment using aminopyridines | |
| TW201612313A (en) | Uses of ligustilide | |
| MX2011007384A (es) | Terapias de combinacion para trastornos neoplásticos. | |
| GB201018154D0 (en) | Method of treatment | |
| TW201612314A (en) | Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases | |
| UA41936U (ru) | Способ лечения крауроза вульвы в детском возрасте |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: TIGENIX, S.A., ES Effective date: 20130815 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JUL 2017 BY CALLINANS Effective date: 20150106 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2018 BY CPA GLOBAL Effective date: 20170608 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2019 BY CPA GLOBAL Effective date: 20180607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2020 BY CPA GLOBAL Effective date: 20190704 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2021 BY CPA GLOBAL Effective date: 20200604 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2022 BY CPA GLOBAL Effective date: 20210603 |
|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP Effective date: 20220121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2023 BY ANAQUA SERVICES Effective date: 20220621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2024 BY ANAQUA SERVICES Effective date: 20230620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2025 BY ANAQUA SERVICES Effective date: 20240619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2026 BY ANAQUA SERVICES Effective date: 20250620 |